4 advances in blood pressure (BP) control in 2024
In a recent review (Denton, 2024) 4 advances in blood pressure (BP) control were identified in 2023.
- Inaccurate data from smart wearable cuffless blood pressure devices – highlight the need to validate such devices to prevent misleading measurements and realise their potential to provide valuable information2
- Single dose of small-interfering RNA zilebesiran – resulted in a decrease in blood pressure that was sustained for 24 weeks3
- Renal denervation – ten-year follow-up data continue to demonstrate a sustained blood-pressure lowering effect of (catheter-based) renal denervation in patients with resistant hypertension4,5
- Non-oral oestrogen in postmenopausal women – oestrogen-only hormone replacement therapy (HRT), given at the lowest dose for the shortest time period was associated with the lowest risk of hypertension.7
Last Reviewed on 24 June 2024